Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4531MR)

This product GTTS-WQ4531MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4531MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3198MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ14974MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ6304MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ12611MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ15989MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ8720MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ4516MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ14261MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW